## WHAT IS CLAIMED IS:

- 1. A method of treating hypertension comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment.
- 2. A method of preventing hypertension comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment.
- 3. A method of treating coronary heart disease comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment.
- 4. A method of treating and preventing eclampsia comprising administering a therapeutically effective amount of an agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels in a patient in need of such treatment.
- 5. An agent capable of reducing uric acid levels selected from the group consisting of: gene therapy, a xanthine oxidase inhibitor; a uricosuric agent; supplements of the uricase protein and a urate channel inhibitor, or pharmaceutically acceptable salts, or combinations therefrom.
- 6. The agent capable of reducing uric acid levels, as recited in Claim 5, which is gene therapy that targets the overexpression of uricase.
- 7. The agent capable of reducing uric acid levels, as recited in Claim 5, which is a xanthine oxidase inhibitor selected from the group consisting of: allopurinol, and carprofen, or pharmaceutically acceptable salt thereof.

- 8. The agent capable of reducing uric acid levels, as recited in Claim 5, which is a uricosuric agent selected from the group consisting of: losartan, benzbromarone, benziodarone, probenecid, sulfinpyrazone, ethebencid, orotic acid, ticrynafen and zoxazolamine, or pharmaceutically acceptable salt thereof.
- 9. The agent capable of reducing uric acid levels, as recited in Claim 5, which is a supplement of uricase protein that is delivered as a conjugate with polyethylene glycol or an alternate delivery system.
- 10. A pharmaceutical composition comprising a renin angiotensin system (RAS) inhibitor, or pharmaceutically acceptable salt thereof and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in Claim 5, and a pharmaceutical carrier.
- 11. A combination therapy comprising the administration, concomitantly, simultaneously or sequentially, of therapeutically effective amounts of a RAS inhibitor, or pharmaceutically acceptable salt thereof, and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in Claim 5.
- 12. The pharmaceutical composition levels as recited in Claim 10, further comprising a diuretic, or pharmaceutically acceptable salt thereof.
- 13. A combination therapy comprising the administration, concomitantly, simultaneously or sequentially, of therapeutically effective amounts of a combination of a RAS inhibitor, or pharmaceutically acceptable salt thereof with a diuretic, or pharmaceutically acceptable salt thereof and the agent, or pharmaceutically acceptable salt thereof, capable of reducing uric acid levels as recited in Claim 5.